← Leaderboards
Sheau-Yu T Hsu
Stanford University
$4,799,110
Attributed
$4,799,110
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $587.4K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,799,110 · 14
By mechanism
R43$2,401,646 · 8
R01$1,387,188 · 1
R41$448,676 · 2
R21$404,600 · 1
R03$157,000 · 1
U54$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Hormones”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Elizabeth A Thom · George Washington University$63,057,764
- Bert W O'Malley · Baylor College Of Medicine$60,670,494
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,978,128
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,218,842
Research focus
HormonesPlayReceptorIn VivoAdrenomedullinRegulationBaseAnimalsAgonistRamp1LeadSignal TransductionExhibitsLigandsComplexCalcitonin Receptor-Like ReceptorReceptor SignalingPeptidesDrug CandidateAnalogBlood VesselsReceptor-Activity-Modifying ProteinCardiovascular SystemNovel Therapeutics
Grant awards (21)
Regenerative peptide therapy to accelerate pressure ulcer healing$367,577
R43 · FY2024 · AG · contact PI
A therapy for improving diabetic ulcer healing$335,342
R43 · FY2023 · DK · contact PI
Development of a treatment-resistant hypertension (RHTN) depot therapeutics$338,152
R43 · FY2019 · HL · contact PI
Development of a novel anti-migraine therapeutics$248,910
R43 · FY2019 · NS · contact PI
Novel Nanomedicine for Treatment-resistant Hypertension (RHTN)$296,941
R43 · FY2017 · HL · contact PI
Novel Therapeutics for Endothelial Dysfunction$290,425
R43 · FY2017 · TR · contact PI
A hormonal therapy for bronchopulmonary dysplasia$299,299
R43 · FY2015 · HL · contact PI
A hormonal therapy for preeclampsia$223,676
R41 · FY2015 · HD · contact PI
Prevention of Preeclampsia-associated preterm births$225,000
R43 · FY2014 · HD · contact PI
Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema$225,000
R41 · FY2014 · CA · contact PI
Role of RAMPs in Intermedin Signaling$273,462
R01 · FY2010 · DK · contact PI
Role of RAMPs in Intermedin Signaling$276,164
R01 · FY2009 · DK · contact PI
Role of RAMPs in Intermedin Signaling$1,600
R01 · FY2009 · DK · contact PI
Role of RAMPs in Intermedin Signaling$276,487
R01 · FY2008 · DK · contact PI
Role of RAMPs in Intermedin Signaling$282,056
R01 · FY2007 · DK · contact PI
Role of RAMPs in Intermedin Signaling$277,419
R01 · FY2006 · DK · contact PI
Identification of Relaxin Receptor Antagonists$215,400
R21 · FY2005 · HD
Identification of Relaxin Receptor Antagonists$189,200
R21 · FY2004 · HD
PHYSIOLOGY OF RELAXIN-INSULIN-LIKE FACTORS$78,500
R03 · FY2002 · HD
CORE--BIOINFORMATICS$0
U54 · FY2002 · HD
PHYSIOLOGY OF RELAXIN-INSULIN-LIKE FACTORS$78,500
R03 · FY2001 · HD